Drugs.com Clinical Trial ResultsOriginal article
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Phase 2positiveABCL635Positive
AI Analysis
Summary
AbCellera announced positive Phase 2 results for ABCL635, an investigational neurokinin 3 receptor antagonist, demonstrating significant reduction in vasomotor symptom frequency and severity with favorable tolerability. The Phase 1/2 trial met its primary endpoints.
Clinical Trial Data
Phase
Phase 1/2
Primary Endpoint
Met
Outcome Details
Significant reduction in frequency and severity of vasomotor symptoms with favorable tolerability profile
Importance:7/10
Sentiment:
0.85
Phase 2 resultsneurokinin 3vasomotor symptomsclinical trialpositive data
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 10, 2026 8:08 PM